Acetylator phenotype in psoriasis.
Acetylator phenotype has been determined with sulfamethazine in 64 psoriatic patients and in 157 normal control subjects. Forty patients (62.5%) versus 90 control subjects (57.3%) were slow acetylators (p = NS). However, 81% of the 27 patients with psoriatic siblings were slow acetylators (p less than 0.05). Slow acetylator phenotype may be a genetic risk factor for the development of psoriasis.